| Hemophilia A
Xyntha vs Hympavzi
Side-by-side clinical, coverage, and cost comparison for hemophilia a.Deep comparison between: Xyntha vs Hympavzi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHympavzi has a higher rate of injection site reactions vs Xyntha based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Hympavzi but not Xyntha, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xyntha
Hympavzi
At A Glance
IV infusion
3 times weekly (prophylaxis)
Factor VIII replacement
SC injection
Weekly
TFPI antagonist
Indications
- Hemophilia A
- Hemophilia A
- Hemophilia B
Dosing
Hemophilia A - On-demand / Bleeding episodes Dose calculated as body weight (kg) x desired FVIII rise (IU/dL) x 0.5; minor bleeds: 20-40 IU/dL target every 12-24 hrs; moderate: 30-60 IU/dL every 12-24 hrs; major: 60-100 IU/dL every 8-24 hrs; IV infusion.
Hemophilia A - Perioperative management Minor surgery: 30-60 IU/dL target every 12-24 hrs for 3-4 days; major surgery: 60-100 IU/dL target every 8-24 hrs until adequate local hemostasis achieved; IV infusion.
Hemophilia A - Routine prophylaxis Adults and adolescents (>=12 years): 30 IU/kg 3 times weekly IV; adjust dose or frequency based on clinical response.
Hemophilia A, Hemophilia B Loading dose 300 mg SC (two 150 mg injections); maintenance 150 mg SC once weekly starting one week after loading dose; consider dose adjustment to 300 mg SC weekly in patients >=50 kg with inadequate bleeding control.
Contraindications
- Life-threatening immediate hypersensitivity reactions, including anaphylaxis, to XYNTHA or its components, including hamster proteins
—
Adverse Reactions
Most common (>=10%) Headache, arthralgia, pyrexia, cough
Postmarketing Inadequate therapeutic response
Most common (>=3%) Injection site reaction, headache, pruritus
Serious Thromboembolic events, hypersensitivity, peripheral swelling, venous thrombosis
Pharmacology
XYNTHA temporarily replaces missing clotting factor VIII needed for effective hemostasis; treatment normalizes activated partial thromboplastin time (aPTT) over the effective dosing period.
Marstacimab-hncq is a human monoclonal IgG1 antibody that targets the Kunitz domain 2 (K2) of tissue factor pathway inhibitor (TFPI), neutralizing TFPI activity and enhancing thrombin generation via the extrinsic coagulation pathway.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xyntha
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Hympavzi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Xyntha
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Hympavzi
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (3/8)
Humana
Xyntha
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Hympavzi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
XynthaView full Xyntha profile
HympavziView full Hympavzi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.